NYSE:PLX Protalix BioTherapeutics (PLX) Stock Price, News & Analysis → The only AI company to buy (From Porter & Company) (Ad) Free PLX Stock Alerts $1.13 -0.01 (-0.88%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$1.11▼$1.1550-Day Range$1.10▼$1.3252-Week Range$1.03▼$2.51Volume345,293 shsAverage Volume368,173 shsMarket Capitalization$82.85 millionP/E Ratio28.25Dividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends Get Protalix BioTherapeutics alerts: Email Address Protalix BioTherapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside785.0% Upside$10.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth425.00%From $0.12 to $0.63 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.56 out of 5 starsMedical Sector503rd out of 929 stocksBiological Products, Except Diagnostic Industry78th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingProtalix BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageProtalix BioTherapeutics has received no research coverage in the past 90 days.Read more about Protalix BioTherapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for PLX. Previous Next 0.0 Dividend Strength Dividend YieldProtalix BioTherapeutics does not currently pay a dividend.Dividend GrowthProtalix BioTherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PLX. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Protalix BioTherapeutics this week, compared to 1 article on an average week.Search Interest8 people have searched for PLX on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows2 people have added Protalix BioTherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Protalix BioTherapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.97% of the stock of Protalix BioTherapeutics is held by insiders.Percentage Held by InstitutionsOnly 16.53% of the stock of Protalix BioTherapeutics is held by institutions.Read more about Protalix BioTherapeutics' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Protalix BioTherapeutics are expected to grow by 425.00% in the coming year, from $0.12 to $0.63 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protalix BioTherapeutics is 28.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.36.Price to Earnings Ratio vs. SectorThe P/E ratio of Protalix BioTherapeutics is 28.25, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 168.61.Price to Book Value per Share RatioProtalix BioTherapeutics has a P/B Ratio of 2.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Protalix BioTherapeutics Stock (NYSE:PLX)Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.Read More PLX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PLX Stock News HeadlinesMay 29 at 8:38 AM | prnewswire.comProtalix BioTherapeutics to Present at the 2024 BIO International ConventionMay 15, 2024 | finance.yahoo.comPLX: First Quarter UpdateMay 13, 2024 | finance.yahoo.comProtalix BioTherapeutics Inc (PLX) Q1 2024 Earnings Call Transcript Highlights: Navigating ...May 12, 2024 | investing.comEarnings call: Protalix BioTherapeutics Q1 2024 financial resultsMay 11, 2024 | finance.yahoo.comProtalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2024 Earnings Call TranscriptMay 10, 2024 | investorplace.comPLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Misses Revenue for Q1 2024May 10, 2024 | msn.comNovavax, Macrogenics, Biofrontera among healthcare moversMay 10, 2024 | msn.comStocks See Support from Higher Chip Stocks and Earnings OptimismMay 10, 2024 | markets.businessinsider.comProtalix BioTherapeutics Inc. Q1 Loss Increases, Misses EstimatesMay 10, 2024 | prnewswire.comProtalix BioTherapeutics Reports First Quarter 2024 Financial and Business ResultsMay 9, 2024 | markets.businessinsider.comProtalix BioTherapeutics earnings: here's what Wall Street expectsMay 3, 2024 | finance.yahoo.comProtalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024March 16, 2024 | seekingalpha.comProtalix BioTherapeutics, Inc. (PLX) Q4 2023 Earnings Call TranscriptMarch 16, 2024 | uk.investing.comEarnings call: Protalix BioTherapeutics reports fiscal year 2023 resultsMarch 15, 2024 | ca.finance.yahoo.comProduction cuts, geopolitical tensions drive oil rallyMarch 15, 2024 | finance.yahoo.comProtalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | finance.yahoo.comPLX: Elfabrio Geographic ExpansionMarch 14, 2024 | finanznachrichten.deProtalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business ResultsMarch 14, 2024 | finance.yahoo.comProtalix BioTherapeutics Inc Reports Revenue Growth and Net Income Gain in FY 2023March 14, 2024 | prnewswire.comProtalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business ResultsMarch 13, 2024 | markets.businessinsider.comHere's what Wall Street expects from Protalix BioTherapeutics's earnings reportMarch 13, 2024 | benzinga.comEarnings Preview: Protalix BioTherapeuticsMarch 9, 2024 | edition.cnn.comProtalix Biotherapeutics, Inc.March 7, 2024 | finance.yahoo.comProtalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024February 23, 2024 | prnewswire.comProtalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor ConferenceSee More Headlines Receive PLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protalix BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today5/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:PLX CUSIPN/A CIK1006281 Webwww.protalix.com Phone201-696-9345Fax972-4988-9489Employees208Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+785.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.04 Trailing P/E Ratio28.25 Forward P/E Ratio9.42 P/E GrowthN/ANet Income$8.31 million Net Margins11.48% Pretax Margin11.35% Return on Equity19.48% Return on Assets7.82% Debt Debt-to-Equity RatioN/A Current Ratio1.38 Quick Ratio0.97 Sales & Book Value Annual Sales$59.65 million Price / Sales1.39 Cash Flow$0.14 per share Price / Cash Flow8.21 Book Value$0.41 per share Price / Book2.76Miscellaneous Outstanding Shares73,316,000Free Float69,672,000Market Cap$82.85 million OptionableOptionable Beta0.90 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Dror Bashan (Age 57)President, CEO & Director Comp: $1.38MMr. Eyal Rubin M.B.A. (Age 48)Senior VP, CFO, Treasurer & Corporate Secretary Comp: $686.78kMr. Yaron Naos (Age 60)Senior Vice President of Operations Comp: $513.82kMs. Yael FellousVice President of Human ResourcesKey CompetitorsAnavex Life SciencesNASDAQ:AVXLTenaya TherapeuticsNASDAQ:TNYAMeiraGTxNASDAQ:MGTXAgenusNASDAQ:AGENReplimune GroupNASDAQ:REPLView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 157,516 shares on 5/20/2024Ownership: 0.215%SG Americas Securities LLCSold 13,139 shares on 5/7/2024Ownership: 0.029%GSA Capital Partners LLPSold 50,667 shares on 5/3/2024Ownership: 0.673%Dror BashanBought 64,516 shares on 10/19/2023Total: $90,322.40 ($1.40/share)View All Insider TransactionsView All Institutional Transactions PLX Stock Analysis - Frequently Asked Questions Should I buy or sell Protalix BioTherapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Protalix BioTherapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PLX shares. View PLX analyst ratings or view top-rated stocks. What is Protalix BioTherapeutics' stock price target for 2024? 1 Wall Street research analysts have issued 12-month price objectives for Protalix BioTherapeutics' stock. Their PLX share price targets range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 785.0% from the stock's current price. View analysts price targets for PLX or view top-rated stocks among Wall Street analysts. How have PLX shares performed in 2024? Protalix BioTherapeutics' stock was trading at $1.78 at the beginning of 2024. Since then, PLX stock has decreased by 36.5% and is now trading at $1.13. View the best growth stocks for 2024 here. How were Protalix BioTherapeutics' earnings last quarter? Protalix BioTherapeutics, Inc. (NYSE:PLX) issued its earnings results on Friday, May, 10th. The company reported ($0.06) earnings per share (EPS) for the quarter. The business earned $3.75 million during the quarter. Protalix BioTherapeutics had a trailing twelve-month return on equity of 19.48% and a net margin of 11.48%. When did Protalix BioTherapeutics' stock split? Protalix BioTherapeutics shares reverse split on Friday, December 20th 2019. The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Protalix BioTherapeutics' major shareholders? Protalix BioTherapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include GSA Capital Partners LLP (0.67%), Virtu Financial LLC (0.21%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Aharon Schwartz, Dror Bashan and Pharma Technologies Ltd Dexcel. View institutional ownership trends. How do I buy shares of Protalix BioTherapeutics? Shares of PLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:PLX) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBiden Nomination CANCELED?The Freeport Society[Urgent!] Generational Wealth GameplanCrypto 101 MediaNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsA once-in-a-century profit opportunity?Digital Mavericks MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.